

UNITED STATES DEPARTMENT OF AGRICULTURE
ANIMAL AND PLANT HEALTH INSPECTION SERVICE

1. REGISTRATION NO. 16-R-0029	CUSTOMER NO. 55	FORM APPROVED OMB NO. 0579-0036
2. HEADQUARTERS RESEARCH FACILITY (Name and Address, as registered with USDA, include Zip Code)		
BOEHRINGER INGELHEIM PHARMACEUTICALS INC 900 RIDGEBURY ROAD, PO BOX 368 RIDGEFIELD, CT 06877		

ANNUAL REPORT OF RESEARCH FACILITY
(TYPE OR PRINT)

(b)(6)(b)(7)(c)

3. REPORTING FACILITY (List all locations where animals were housed or used in actual research, testing, teaching, or experimentation, or held for these purposes. Attach additional sheets if necessary.)

FACILITY LOCATIONS(sites)

See Attached Listing
Research & Development Animal Facilities

NOV 21 2006

REPORT OF ANIMALS USED BY OR UNDER CONTROL OF RESEARCH FACILITY (Attach additional sheets if necessary or use APHIS FORM 7023A)

A. Animals Covered By The Animal Welfare Regulations	B. Number of animals being bred, conditioned, or held for use in teaching, testing, experiments, research, or surgery but not yet used for such purposes.	C. Number of animals upon which teaching, research, experiments, or tests were conducted involving no pain, distress, or use of pain-relieving drugs.	D. Number of animals upon which experiments, teaching, research, surgery, or tests were conducted involving accompanying pain or distress to the animals and for which appropriate anesthetic, analgesic, or tranquilizing drugs were used.	E. Number of animals upon which teaching, experiments, research, surgery or tests were conducted involving accompanying pain or distress to the animals and for which the use of appropriate anesthetic, analgesic, or tranquilizing drugs would have adversely affected the procedures, results, or interpretation of the teaching, research, experiments, surgery, or tests. (An explanation of the procedures producing pain or distress in these animals and the reasons such drugs were not used must be attached to this report)	F. TOTAL NO. OF ANIMALS (Cols. C + D + E)
4. Dogs	53	80	25	1	106
5. Cats	0	0	0	0	0
6. Guinea Pigs	0	34	81	300	415
7. Hamsters	0	0	440	949	1389
8. Rabbits	0	0	0	0	0
9. Non-Human Primates	67	88	9	55	152
10. Sheep	0	0	0	0	0
11. Pigs	0	0	0	0	0
12. Other Farm Animals	0	0	0	0	0
13. Other Animals	0	0	0	0	0

ASSURANCE STATEMENTS


- 1) Professionally acceptable standards governing the care, treatment, and use of animals, including appropriate use of anesthetic, analgesic, and tranquilizing drugs, prior to, during, and following actual research, teaching, testing, surgery, or experimentation were followed by this research facility.
- 2) Each principal investigator has considered alternatives to painful procedures.
- 3) This facility is adhering to the standards and regulations under the Act, and it has required that exceptions to the standards and regulations be specified and explained by the principal investigator and approved by the Institutional Animal Care and Use Committee (IACUC). A summary of all the exceptions is attached to this annual report. In addition to identifying the IACUC-approved exceptions, this summary includes a brief explanation of the exceptions, as well as the species and number of animals affected.
- 4) The attending veterinarian for this research facility has appropriate authority to ensure the provision of adequate veterinary care and to oversee the adequacy of other aspects of animal care and use.

CERTIFICATION BY HEADQUARTERS RESEARCH FACILITY OFFICIAL
(Chief Executive Officer or Legally Responsible Institutional official)

I certify that the above is true, correct, and complete (7 U.S.C. Section 2143)

SIGNATURE OF C.E.O. OR INSTITUTIONAL OFFICIAL	NAME & TITLE OF C.E.O. OR INSTITUTIONAL OFFICIAL (Type or Print)	DATE SIGNED
(b)(6)(b)(7)(c)	(b)(6)(b)(7)(c)	11/17/06


(b)(6)(b)(7)(c)



Facility Registration Number 16-R-0029

E4

1 dog assigned to Column E of this report was included in a nonclinical laboratory study to evaluate (b) (4) of a test compound in accordance to Food and Drug Administration requirements under Good Laboratory Practice regulations 21 CFR 58. This animal received a high dose of a test agent by oral gavage and experienced (b) (4) (b)(4) of receiving the test agent and died suddenly before medical intervention could be provided.



E6

300 guinea pigs assigned to Column E of this report were used in nonclinical laboratory studies (b)(4) specific trace component. The animals (b)(4) through administration of that (b)(4) adjuvant, followed (b)(4). The (b)(4) was expressed as a degree (b)(4) in the guinea pigs. The (b)(4) was measured at (b)(4) time point. No analgesics were administered during the (b)(4) time period because those agents had the potential to (b)(4) which was the end point that was to be measured and therefore could interfere with the accurate interpretation of the properties (b)(4) (b)(4) (b)(4)

Facility Registration Number 16-R-0029

E7

949 hamsters assigned to Column E of this report underwent (b)(4) surgical procedures for the purpose of creating (b)(4) models for use in evaluating and identifying compounds that may be beneficial in treatment of humans. Although the animals received peri-operative analgesics and anesthesia they did not receive continuous analgesics during the remainder of the study because the side effects of such drugs could (b)(4) which could result in increased mortality of the animals.

E9

39 squirrel monkeys assigned to Column E of this report were used as a model (b)(4) immunity in which (b)(4) dosed with test compound by oral route and (b)(4) with (b)(4). Although (b)(4) was minimized, the animals experienced skin irritation, swelling and/or some degree (b)(4). Analgesics were not administered during the post-challenge period to avoid interference with the development of (b)(4).

16 rhesus macaques assigned to Column E of this report were used in a nonclinical laboratory study to evaluate (b)(4) of a test article in accordance to the Food and Drug Administration requirements under Good Laboratory Practice regulations, 21 CFR 58. The animals were used in a (b)(4) study to determine potential (b)(4) (b)(4) of the test article that was administered by oral gavage. Following (b)(4), the animals developed diarrhea, vomiting, and progressive weight loss. The animals were given supportive therapy, including fluid therapy, or were euthanized, but were not given other drugs such as analgesics that might cause reversal of the (b)(4) of the test article or induce their own inherent (b)(4) or drug-drug interactions.